Postmortem THC Ratios Are Not Universal Correction Factors

A median ratio between central and peripheral postmortem blood cannot safely be used as a fixed multiplier to reconstruct an individual’s earlier THC concentration. A human case series found substantial variation, including ratios below and above one.

What was compared

Holland and colleagues selected 19 adult death cases with a positive postmortem urine cannabinoid screen. Cardiac blood represented the central specimen and iliac-vein blood the peripheral specimen. They measured THC, 11-hydroxy-THC and THCCOOH and separately used cannabinoid-negative postmortem cases for method validation.

This was an observational human postmortem study. It did not administer cannabis at a known time or dose before death. Three cases had available antemortem blood, a useful but very small subset for evaluating changes across the death interval.

A median concealed wide ranges

The median central-to-peripheral ratio was 1.5 for THC, with a range of 0.3–3.1. The corresponding median ratios were 1.7 for 11-hydroxy-THC and 1.8 for THCCOOH. Ratios below one demonstrate that central blood was not invariably higher.

Central–peripheral differences were not statistically significant for THC or 11-hydroxy-THC in the reported comparisons. THCCOOH did show a significant difference. Trends involving postmortem interval did not reach statistical significance. These results do not support treating all three analytes as interchangeable redistribution markers.

Why reconstruction requires restraint

A selected urine-positive case series is not a representative sample of every death investigation. Some specimens also had analytical interferences, and the antemortem and postmortem samples used different preservatives. Sampling site, storage and interval therefore remain relevant.

Dividing a central THC result by 1.5 would substitute a group median for the unknown behavior of one case. It would not establish the concentration at an earlier crash, the last-use time, or a causal role in death.

A defensible report identifies the precise sampling site and the limits of any comparison. The distinction between measured exposure and functional effects, discussed in our THC impairment analysis, remains necessary even before adding the further uncertainty introduced by postmortem changes.

Primary research

Michael G. Holland and colleagues. Forensic science international (2011). Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us